Jessica Steen, OD: AbbVie/Allergan: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Alcon: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Astellas: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Balance Ophthalmics: Consulting Fees (); Bausch + Lomb: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Carl Zeiss Meditec: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Clearside Biomedical: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Dompe: Speaker's Bureau (honoraria or other compensation) (); Eyenovia: Consulting Fees (); Glaukos: Consulting Fees (); iCare: Consulting Fees (); Ocuterra: Consulting Fees (); Opus Genetics: Consulting Fees (); Orasis: Consulting Fees (); Radius: Consulting Fees (); Tarsus: Consulting Fees (); Thea Pharma: Speaker's Bureau (honoraria or other compensation) (); Viatris: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) ()
This course will offer a practical approach to the evaluation and application of OCT-based parameters to clinical case examples of patients with vitreoretinal and optic nerve disease. High risk biomarkers for progression of age-related macular degeneration and retinal OCT biomarkers which imply risk of systemic disease will be highlighted.
Learning Objectives:
Upon conclusion of this activity, attendees will be able to:
Evaluate current uses and modalities of OCT in ophthalmic imaging
Interpret retinal imaging to diagnose and determine progression of retinal diseases
Analyze imaging to aid in diagnosis and determination of progression of optic nerve disease
Recognize limitations and artifacts of OCT-based imaging
